References
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;31:1281-357
- van den Meiracker AH. A global approach to hypertension. EuroIntervention 2013;9(Suppl R):R16-20
- Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007;67:95-106
- Rump LC. Efficacy and tolerability of the fixed lercanidipine–enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010;60:124-30
- Scholze J, Bramlage P, Trenkwalder P, Kreutz R. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011;12:2771-9
- Maldonado J, Pereira T, Tavares A. Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Drugs R D 2014;14:147-54
- Arnaout S; DUAL Investigators Study Group. Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study. Curr Med Res Opin 2015;31:187-90
- Breitscheidel L, Ehlken B, Kostev K, et al. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J Med Econ 2012;15:155-65
- Eckert S, Freytag SB, Müller A, Klebs SH. Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors. Blood Press 2013;22(Suppl 1):11-21